Wang D, Sun D, Wang X, Peng X, Ji Y, Tang L
MedComm (2020). 2024; 5(7):e634.
PMID: 38988492
PMC: 11233931.
DOI: 10.1002/mco2.634.
Gordon D, Kivitz A, Singhal A, Burt D, Bangs M, Huff E
ACR Open Rheumatol. 2023; 5(2):63-70.
PMID: 36604812
PMC: 9926068.
DOI: 10.1002/acr2.11517.
Yao T, Xiao H, Wang H, Xu X
Int J Mol Sci. 2022; 23(18).
PMID: 36142231
PMC: 9499226.
DOI: 10.3390/ijms231810328.
Gaur R, Mensah K, Stricker J, Adams M, Parton A, Cedzik D
Arthritis Res Ther. 2022; 24(1):199.
PMID: 35982464
PMC: 9386913.
DOI: 10.1186/s13075-022-02850-6.
Kim M, Choe Y, Lee S
Immune Netw. 2022; 22(1):e8.
PMID: 35291656
PMC: 8901706.
DOI: 10.4110/in.2022.22.e8.
p38 MAPKs - roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets.
Brennan C, Emerson Jr C, Owens J, Christoforou N
JCI Insight. 2021; 6(12).
PMID: 34156029
PMC: 8262482.
DOI: 10.1172/jci.insight.149915.
Pseudomonas aeruginosa induces p38MAP kinase-dependent IL-6 and CXCL8 release from bronchial epithelial cells via a Syk kinase pathway.
Coates M, Alton E, Rapeport G, Davies J, Ito K
PLoS One. 2021; 16(2):e0246050.
PMID: 33524056
PMC: 7850485.
DOI: 10.1371/journal.pone.0246050.
Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis.
Lopez-Pedrera C, Barbarroja N, Patino-Trives A, Luque-Tevar M, Collantes-Estevez E, Escudero-Contreras A
Int J Mol Sci. 2020; 21(23).
PMID: 33260629
PMC: 7731249.
DOI: 10.3390/ijms21239067.
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19.
Massalska M, Maslinski W, Ciechomska M
Cells. 2020; 9(8).
PMID: 32796683
PMC: 7464410.
DOI: 10.3390/cells9081876.
Effect of the p38 MAPK inhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses.
Bauquier J, Tudor E, Bailey S
J Vet Intern Med. 2020; 34(5):2109-2116.
PMID: 32700419
PMC: 7517855.
DOI: 10.1111/jvim.15847.
An overview of mammalian p38 mitogen-activated protein kinases, central regulators of cell stress and receptor signaling.
Han J, Wu J, Silke J
F1000Res. 2020; 9.
PMID: 32612808
PMC: 7324945.
DOI: 10.12688/f1000research.22092.1.
Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma.
Lambert W, Pasini S, Collyer J, Formichella C, Ghose P, Carlson B
Sci Rep. 2020; 10(1):8535.
PMID: 32444682
PMC: 7244559.
DOI: 10.1038/s41598-020-65374-6.
Host-Directed Antiviral Therapy.
Kumar N, Sharma S, Kumar R, Tripathi B, Barua S, Ly H
Clin Microbiol Rev. 2020; 33(3).
PMID: 32404434
PMC: 7227448.
DOI: 10.1128/CMR.00168-19.
Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.
Guenthoer P, Fuchs K, Reischl G, Quintanilla-Martinez L, Gonzalez-Menendez I, Laufer S
Inflammopharmacology. 2019; 27(6):1217-1227.
PMID: 31037574
DOI: 10.1007/s10787-019-00593-6.
MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression.
Soni S, Anand P, Padwad Y
J Exp Clin Cancer Res. 2019; 38(1):121.
PMID: 30850014
PMC: 6408796.
DOI: 10.1186/s13046-019-1115-1.
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith B, Wang S, Jaime-Figueroa S, Harbin A, Wang J, Hamman B
Nat Commun. 2019; 10(1):131.
PMID: 30631068
PMC: 6328587.
DOI: 10.1038/s41467-018-08027-7.
Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion.
Scarneo S, Mansourati A, Eibschutz L, Totzke J, Roques J, Loiselle D
Sci Rep. 2018; 8(1):17058.
PMID: 30451876
PMC: 6242965.
DOI: 10.1038/s41598-018-35189-7.
Critical role of IL-1α in IL-1β-induced inflammatory responses: cooperation with NF-κBp65 in transcriptional regulation.
Singh A, Fechtner S, Chourasia M, Sicalo J, Ahmed S
FASEB J. 2018; 33(2):2526-2536.
PMID: 30272996
PMC: 6338654.
DOI: 10.1096/fj.201801513R.
Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3.
Ansideri F, Macedo J, Eitel M, El-Gokha A, Zinad D, Scarpellini C
ACS Omega. 2018; 3(7):7809-7831.
PMID: 30087925
PMC: 6072243.
DOI: 10.1021/acsomega.8b00668.
A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers.
Cheriyan V, Alsaab H, Sekhar S, Venkatesh J, Mondal A, Vhora I
Oncotarget. 2018; 9(51):29680-29697.
PMID: 30038713
PMC: 6049854.
DOI: 10.18632/oncotarget.25671.
